CL King Initiates Coverage On Conmed with Buy Rating, Announces Price Target of $140
Portfolio Pulse from richadhand@benzinga.com
CL King analyst Kristen Stewart initiates coverage on Conmed (NYSE:CNMD) with a Buy rating and announces a price target of $140.
May 22, 2023 | 12:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Conmed receives a Buy rating from CL King analyst Kristen Stewart, with a price target of $140.
The Buy rating and price target of $140 announced by CL King analyst Kristen Stewart for Conmed (NYSE:CNMD) is a positive signal for the stock. This recommendation suggests that the analyst believes the stock has potential for growth in the short term, which could lead to an increase in its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100